Investigation of The Effect of Cenicriviroc (CVC) Plus FTC/TDF on Cardiovascular Disease Risk Factors
A Phase 2b Randomized, Double-Blind, Double-Dummy Trial of 100 or 200 mg Once-Daily Doses of Cenicriviroc (CVC, TBR-652) or Once-Daily EFV, Each With Open-Label FTC/TDF, in HIV-1-Infected, Antiretroviral Treatment-Naïve, Adult Patients With Only CCR5-Tropic Virus
Sponsor: Tobira Therapeutics, Inc.
Terminated
Low enrollment
Other terminated trials from Tobira Therapeutics, Inc.
More terminations from Tobira Therapeutics, Inc.
A observational or N/A phase clinical study on HIV Infection, this trial is terminated or withdrawn. The trial is conducted by Tobira Therapeutics, Inc. and has accumulated 7 data snapshots since 2011. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Jan 2021 — Jul 2024 [monthly]
Terminated
-
Jun 2018 — Jan 2021 [monthly]
Terminated
-
Apr 2018 — Jun 2018 [monthly]
Terminated
Phase: NA → None
▶ Show 2 earlier versions
-
Feb 2017 — Apr 2018 [monthly]
Terminated NA
-
Jan 2017 — Feb 2017 [monthly]
Terminated NA
First recorded
Sep 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Tobira Therapeutics, Inc.
- University of California, San Francisco
For direct contact, visit the study record on ClinicalTrials.gov .